Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
HER2 in non-small cell lung cancer comprises two distinct conditions: genomic mutations (e.g., exon 20 insertions) treated with Tyrosine Kinase Inhibitors (TKIs), and protein overexpression detected by IHC, treated with Antibody-Drug Conjugates (ADCs). Confusing them leads to incorrect therapy, as TKIs are ineffective for overexpression alone.
Related Insights
Effective treatment of HER2-driven NSCLC requires more than just identifying mutations. HER2 is a multiplexed biomarker where both genetic mutations (TKD and non-TKD) and protein overexpression (via IHC) are independently actionable. Comprehensive testing is crucial to ensure patients are eligible for the full range of available targeted therapies, including TKIs and ADCs.
Historically, HER2-mutated lung cancer was treated with cytotoxic chemotherapy, unlike other oncogene-driven cancers that used targeted therapies upfront. Zongertinib's approval as a first-line oral TKI marks a significant philosophical shift, aligning its treatment strategy with the biomarker-driven care standard in lung oncology.
The specific type of HER2 mutation significantly impacts TKI efficacy. YVMA exon 20 insertions show the highest response rates. Other TKD (tyrosine kinase domain) mutations perform moderately well, while non-TKD mutations respond poorly. This molecular nuance is critical for predicting treatment success and managing patient expectations.
For HER2-mutant NSCLC, Zongertinib (a TKI) is now the first-line choice. While TKIs show activity after ADCs like TDXD, the effectiveness of using an ADC after TKI failure remains an unproven but critical clinical question for oncologists.
In NSCLC, "HER2 positive" can mean one of three largely separate conditions: rare exon 20 mutations (~2%), rare gene amplifications (~2%), or more common protein overexpression (20-30%). Understanding these distinctions is critical for accurate biomarker testing and selecting appropriate therapies.
Unlike older HER2 tyrosine kinase inhibitors (TKIs) that also target EGFR, zungertinib is highly selective. This specificity prevents common EGFR-mediated side effects like severe diarrhea and acneform rash, resulting in a much better-tolerated treatment for patients with HER2-mutant lung cancer.
The new treatment paradigm for HER2-positive lung cancer will likely involve sequencing a TKI like zongertinib first, followed by an antibody-drug conjugate (ADC). Early data suggests that the efficacy of TKIs is significantly reduced when used after an ADC, making the TKI-first approach critical for maximizing patient outcomes.
The recent first-line FDA approval of the oral TKI zungertinib fundamentally alters the treatment paradigm for HER2-mutant non-small cell lung cancer. This shifts the standard of care away from initial platinum-based chemotherapy, forcing oncologists to reconsider the sequencing of TKIs, antibody-drug conjugates, and chemotherapy.
The list of oncogenic drivers where single-agent immunotherapy is ineffective should be expanded beyond EGFR and ALK to include HER2 mutations. Citing a study where the response rate to immunotherapy was zero percent for these patients, experts advise against using it in this specific molecular subtype.
While most HER2 mutations in NSCLC occur in the tyrosine kinase domain (TKD), about 20% arise elsewhere. Current HER2 TKIs show high activity against TKD mutations but have significantly lower response rates (~30%) for non-TKD mutations, highlighting an area of unmet need for this patient subset.
